Pre-Clinical Applications of Transgenic Mouse Mammary Cancer Models
暂无分享,去创建一个
P. Brown | K. Desai | R. Lubet | C. Couldrey | A. Calvo | C. Kavanaugh | J. Green
[1] A. Feldman,et al. Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. , 2002, Cancer research.
[2] L. Wakefield,et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.
[3] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. Green,et al. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. , 2001, Cancer research.
[5] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[6] Thomas Ludwig,et al. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice , 2001, Oncogene.
[7] Curtis C. Harris,et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.
[8] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[9] S. Singletary,et al. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast , 2001, Journal of surgical oncology.
[10] T. Hla,et al. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.
[11] M. Hitt,et al. Combined Treatment of a Murine Breast Cancer Model with Type 5 Adenovirus Vectors Expressing Murine Angiostatin and IL-12: A Role for Combined Anti-Angiogenesis and Immunotherapy1 , 2001, The Journal of Immunology.
[12] P. Musiani,et al. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. , 2001, Cancer research.
[13] M. Dowsett,et al. Recent advances in the clinical application of aromatase inhibitors , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[14] J. Ward,et al. Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis1 2 , 2001, The Journal of Immunology.
[15] A. Senderowicz,et al. Small molecule modulators of cyclin-dependent kinases for cancer therapy , 2000, Oncogene.
[16] K. Korach,et al. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. , 2000, Cancer research.
[17] J. Masferrer,et al. COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.
[18] John N. Hutchinson,et al. Transgenic mouse models of human breast cancer , 2000, Oncogene.
[19] Wen-Hwa Lee,et al. Lessons learned from BRCA1 and BRCA2 , 2000, Oncogene.
[20] F. Kittrell,et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. , 2000, The American journal of pathology.
[21] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[22] M. Osborne,et al. Breast cancer chemoprevention. , 2000, American journal of surgery.
[23] S. Hilsenbeck,et al. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] J. Green,et al. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. , 2000, Cancer research.
[25] J. Kaprio,et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.
[26] E. Jaffee,et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.
[27] J A Hanley,et al. Nested caseÐcontrol study of the effects of non- steroidal anti-inflammatory drugs on breast cancer risk and stage , 2000 .
[28] W. Muller,et al. Mammary gland neoplasia: insights from transgenic mouse models , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[29] R. Diehl,et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. , 2000, Cancer research.
[30] F. Leenders,et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation , 2000, Oncogene.
[31] S. Deming,et al. Cell cycle basis for the onset and progression of c-Myc-induced, TGFα-enhanced mouse mammary gland carcinogenesis , 2000, Oncogene.
[32] E. Ozer,et al. BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study. , 2000, Applied immunohistochemistry & molecular morphology : AIMM.
[33] J. Dennis,et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice , 2000, Nature Medicine.
[34] W. Deppert,et al. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland , 2000, Oncogene.
[35] R. Dickson,et al. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models , 2000, Oncogene.
[36] R. Cardiff,et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.
[37] H. Varmus,et al. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.
[38] W. Muller,et al. Signal transduction in mammary tumorigenesis: a transgenic perspective , 2000, Oncogene.
[39] L. Hennighausen,et al. Transforming growth factor alpha and mouse models of human breast cancer , 2000, Oncogene.
[40] E. Sandgren,et al. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice , 2000, Oncogene.
[41] Cheryl Jorcyk,et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.
[42] P. Musiani,et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.
[43] L. Hennighausen. Mouse models for breast cancer , 2000, Oncogene.
[44] R. Herbert,et al. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene , 1999, Breast Cancer Research and Treatment.
[45] R. Laucirica,et al. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model , 1999, Oncogene.
[46] F. Kittrell,et al. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice , 1999, Oncogene.
[47] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[48] T. Thomas,et al. Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice. , 1999, Cancer letters.
[49] A. Sckell,et al. Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.
[50] P. Musiani,et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[51] W. Muller,et al. Oncogenic Activating Mutations in the neu/erbB‐2 Oncogene Are Involved in the Induction of Mammary Tumors , 1999, Annals of the New York Academy of Sciences.
[52] H. Hibshoosh,et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice , 1999, Oncogene.
[53] S. Tsai,et al. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B , 1999, Oncogene.
[54] W. Muller,et al. Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. , 1999, Journal of cell science.
[55] S. Fox,et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] R. Tekmal,et al. Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. , 1999, Endocrine-related cancer.
[57] H. Varmus,et al. A Mouse Mammary Tumor Virus-Wnt-1 Transgene Induces Mammary Gland Hyperplasia and Tumorigenesis in Mice Lacking Estrogen Receptor-α , 1999 .
[58] P. Watson,et al. Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene , 1999, Oncogene.
[59] G. Lyman,et al. The effects of NSAIDs on breast cancer prognostic factors. , 1999, Oncology reports.
[60] T. Slaga,et al. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. , 1999, Journal of the National Cancer Institute.
[61] L. Esserman,et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.
[62] N. Saarinen,et al. Dietary phytoestrogens and their role in hormonally dependent disease. , 1998, Toxicology letters.
[63] A. Amici,et al. Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.
[64] F. Graham,et al. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[65] R. Cardiff,et al. Active signaling by Neu in transgenic mice , 1998, Oncogene.
[66] K. Buetow,et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression , 1998, International journal of cancer.
[67] J. Sundberg,et al. Lactation-induced WAP-SV40 Tag Transgene Expression in C57BL/6J Mice Leads to Mammary Carcinoma , 1998, Transgenic Research.
[68] T. Kipps,et al. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. , 1998, Cancer research.
[69] R. Montesano,et al. Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. , 1998, Developmental biology.
[70] R. Herbert,et al. Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene , 1998, Breast Cancer Research and Treatment.
[71] M. Malumbres,et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. , 1998, Cancer research.
[72] F. Kittrell,et al. A transgenic mouse model for mammary carcinogenesis , 1998, Oncogene.
[73] D. Troyer,et al. A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.
[74] M. Shibata,et al. The C3(1)/SV40 T Antigen Transgenic Mouse Model of Prostate and Mammary Cancer , 1998, Toxicologic pathology.
[75] N. Kohl,et al. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. , 1997, Trends in pharmacological sciences.
[76] J. Green,et al. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice , 1997, Molecular carcinogenesis.
[77] R. Herbert,et al. Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue , 1997, Breast Cancer Research and Treatment.
[78] D. Bortner,et al. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.
[79] D. Hanahan,et al. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.
[80] R. Tekmal,et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. , 1996, Cancer research.
[81] R. Cardiff,et al. Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.
[82] K. Friedrich,et al. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. , 1995, Pathology, research and practice.
[83] A. Pellicer,et al. Promoter demethylation in MMTV/N‐rasN transgenic mice required for transgene expression and tumorigenesis , 1995, Molecular carcinogenesis.
[84] R. Palmiter,et al. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.
[85] D. Troyer,et al. Dietary lipids and calorie restriction affect mammary tumor incidence and gene expression in mouse mammary tumor virus/v-Ha-ras transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Moser,et al. ApcMin: a mouse model for intestinal and mammary tumorigenesis. , 1995, European journal of cancer.
[87] R. Coffey,et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[88] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[89] Emma Lees,et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.
[90] E. Wagner,et al. Oncogenes in the study of endothelial cell growth and differentiation. , 1994, Seminars in cancer biology.
[91] R. Weinberg,et al. Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.
[92] G. Casey,et al. Functional evidence for a breast cancer growth suppressor gene on chromosome 17. , 1993, Human molecular genetics.
[93] G. Stamp,et al. Nonuniform expression of a mouse mammary tumor virus-driven int-2/Fgf-3 transgene in pregnancy-responsive breast tumors. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[94] R. Nusse. The Wnt gene family in tumorigenesis and in normal development , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[95] R. Strange,et al. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. , 1992, Development.
[96] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[97] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[98] H. Varmus,et al. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells , 1992, Molecular and cellular biology.
[99] H. Varmus,et al. Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.
[100] O. Isaksson,et al. Induction of mammary adenocarcinomas in metallothionein promoter‐human growth hormone transgenic mice , 1991, International journal of cancer.
[101] R. Meiss,et al. Mammary carcinogenesis induced byN-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) inBALB/c mice , 1991, Breast Cancer Research and Treatment.
[102] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[103] Harold L. Moses,et al. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights , 1990, Cell.
[104] B. Hogan,et al. Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.
[105] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[106] A. Whittemore,et al. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. , 1988, American journal of epidemiology.
[107] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[108] B. Groner,et al. Targeted c‐myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. , 1988, The EMBO journal.
[109] P. Leder,et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.
[110] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[111] A. Levine,et al. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex , 1986, Journal of virology.
[112] W. McGuire,et al. Current status of estrogen and progesterone receptors in breast cancer , 1977, Cancer.
[113] C. Ip. Mammary tumorigenesis and chemoprevention studies in carcinogen-treated rats , 2005, Journal of Mammary Gland Biology and Neoplasia.
[114] R. Clarke. Animal models of breast cancer: Their diversity and role in biomedical research , 2005, Breast Cancer Research and Treatment.
[115] D. Barnes,et al. Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.
[116] S. Ménard,et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.
[117] E. Scanziani,et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice , 2001, Gene Therapy.
[118] W. R. Bishop,et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo , 2000, Cancer Chemotherapy and Pharmacology.
[119] Costantino,et al. RESPONSE: re: tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study , 1999, Journal of the National Cancer Institute.
[120] M. Belury,et al. Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. , 1999, Nutrition and cancer.
[121] H. Varmus,et al. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. , 1999, Cancer research.
[122] W. Farrar,et al. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. , 1999, Oncology reports.
[123] M. Gould,et al. The genetic components of susceptibility to breast cancer in the rat. , 1999, Progress in experimental tumor research.
[124] E. Lander,et al. Mouse mammary tumor virusyv-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4 (allelotypeyloss of heterozygosityytumor suppressor geneytransgenic miceyexperimental breast neoplasms) , 1997 .
[125] V. Kataja,et al. Prognostic significance of TGF-alpha expression in breast cancer. , 1996, Acta oncologica.
[126] V. Kataja,et al. Prognostic significance of TGF-α expression in breast cancer , 1996 .
[127] R. Cardiff,et al. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.
[128] R. Tennant,et al. Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. , 1993, Carcinogenesis.
[129] J. Foekens,et al. Prognostic factors and response to therapy in breast cancer. , 1993, Cancer surveys.
[130] B. Hogan,et al. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.
[131] H. Moses,et al. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. , 1990, Cell.